Détail de l'auteur
Documents disponibles écrits par cet auteur (330)
Rapport
OEDT = EMCDDA ; D. HEDRICH ; K. PALCZAK ; K. KEPA ; N. SINGLETON | Lisbon : OEDT / EMCDDA | Manuals | 2021This manual provides a step-by-step guide for those involved in planning and managing infectious diseases and drug services, focusing on how to identify barriers to and opportunities for improving provision of HCV testing and access to treatment[...]Rapport
J. MARSDEN ; A. C. OGBORNE ; M. FARRELL ; RISH B. ; OMS / WHO ; UNDCP ; OEDT = EMCDDA | Genève : OMS / WHO | 2000These guidelines describe methods for the evaluation of treatment services and systems for substance use disorders. The guides are intended to be a companion resource to the WHO/UNDCP/EMCDDA workbook series on the evaluation of costs and effects[...]Rapport
FRANÇAIS : Le présent projet avait pour objectif de rassembler l'information relative aux programmes de formation post-graduée sur les drogues existant en Europe, et d'étudier l'utilité et la faisabilité d'une mise en réseau de ces programmes [...]Rapport
Commission des communautés européennes = Commission of the European communities ; OEDT = EMCDDA | 1993FRANÇAIS : Ce document constitue un recueil de la majorité des textes officiels de la communauté européenne depuis environ vingt ans. Il s'agit d'une des premières publications de l'Observatoire Européen des Drogues dont les objectifs et l'org[...]Rapport
OEDT = EMCDDA ; M. EVANS-BROWN ; A. GALLEGOS ; R. SEDEFOV ; A. ALMEIDA ; R. CHRISTIE ; P. DUQUE ; A. GALLEGOS ; R. JORGE ; J. DE MORAIS | Lisbon : OEDT / EMCDDA | Risk assessments, ISSN 1725-4493 | 2020This publication presents the data and findings of the risk assessment on N,N-diethyl-2-[[4-(1-methylethoxy)phenyl]methyl]-5-nitro-1H-benzimidazole-1- ethanamine (isotonitazene), carried out by the extended Scientific Committee of the EMCDDA on [...]Rapport
This paper highlights evidence of legislative activity related to new synthetic drugs as an indicator of Member States’ commitment to the issue. It also examines to what extent legal activity may be attributed to the EU action plan on drugs. Am[...]Rapport
This thematic paper looks at the extent to which legislative attention was paid in the period 2000-2004 to actions considered by Member States to be of high priority at the outset of the strategy and action plan. Over 250 legal texts were analys[...]Rapport
The open sale of cannabis products in Europe has raised concerns among policymakers, both with regard to the legal status of these products and their potential for harm. The products are marketed for their low THC (tetrahydrocannabinol) content,[...]Rapport
OEDT = EMCDDA ; M. P. SCHAUB ; J. Y. C. LEE ; A. PIRONA | Lisbon : OEDT / EMCDDA | EMCDDA Papers, ISSN 2315-1463 | 2018This paper presents results from a scoping study on the availability of smartphone-based applications in the drugs field within a European and global context. It explores the range of m-health applications available to users and professionals s[...]Rapport
This paper aims to provide an overview on the development of the evaluation process of the EU Strategy and Action Plan on Drugs. A large part of the initiatives and action impacting on the drug phenomenon are under the direct responsibility of [...]Chapitre
OEDT = EMCDDA | 2012FRANÇAIS : L'usage de drogue est associé directement et indirectement à une grande diversité de conséquences négatives sur la santé et la vie sociale. Ces problèmes concernent dans une mesure disproportionnée les usagers d'opiacés de longue dur[...]Rapport
This risk assessment report presents the summary findings and the conclusion of the risk assessment carried out by the Scientific Committee of the EMCDDA on MDMB-4en-PINACA. The report is intended for policymakers and decision-makers in the inst[...]Rapport
OEDT = EMCDDA ; A. M. DINES ; D. M. WOOD ; P. I. DARGAN | Lisbon : OEDT / EMCDDA | Risk assessments, ISSN 1725-4493 | 2014This report presents the data and findings of the risk assessment on the new psychoactive substance, 1-(1,3-benzodioxol-5-yl)-2-(pyrrolidin-1-yl)pentan-1-one (MDPV), that was conducted by the Scientific Committee of the EMCDDA. Concerns over t[...]Rapport
ENGLISH: What is the evidence base for the medical use of cannabis and cannabinoids? What is the difference between cannabis preparations and medicinal products and why is this important? How is this issue regulated in the EU? These and other q[...]Congrès
Reitox Academy for Baltic countries: Monitoring trends in and responses to drug-related infectious diseases among people who inject drugs (21-22 November 2013; Tallinn) ; OEDT = EMCDDA, Organisateur de réunion ; European Centre for Disease Prevention and Control, Organisateur de réunion | Lisbon : OEDT / EMCDDA | 2013This meeting, a regional Reitox Academy held in Tallinn (21-22 November 2013) contributed to maximising synergies at national level between institutions and experts in the fields of drug monitoring and infectious disease surveillance in four cou[...]Congrès
3rd Meeting on detecting and responding to outbreaks of HIV among people who inject drugs (18 November 2013; Bucharest) ; Roundtable on the HIV situation among people who inject drugs in Romania (19 November 2013; Bucharest) ; OEDT = EMCDDA, Organisateur de réunion ; European Centre for Disease Prevention and Control, Organisateur de réunion | Lisbon : OEDT / EMCDDA | 2013This expert meeting held in Bucharest (18-19 November 2013) provided an important opportunity for sharing knowledge and best practice among experts from six countries in the south and south-east of the European region (Cyprus, Greece, Hungary, M[...]Rapport
This publication is the first in a series dedicated to prevalent illicit synthetic stimulant drugs, also known as amphetamine-type stimulants (ATS). The ATS category is made up of two groups of substances. This study focuses on the supply and us[...]Rapport
This report examines the relatively recent emergence of methamphetamine production in Afghanistan and identifies actions that may be taken in Europe to mitigate the risks. The publication stresses the importance of increasing awareness on the is[...]Rapport
This report provides a comprehensive overview of the methamphetamine market in the European Union. It assesses the current threat situation regarding current trends in production, trafficking and distribution.Rapport
OEDT = EMCDDA ; D. M. WOOD ; P. I. DARGAN | Lisbon : OEDT / EMCDDA | Risk assessments, ISSN 1725-4493 | 2014This report presents the data and findings of the risk assessment on the new psychoactive substance, 2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone (methoxetamine), that was conducted by the Scientific Committee of the EMCDDA. Concerns over t[...]Rapport
This publication presents the data and findings of the risk assessment on 2-methoxy-N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]acetamide (methoxyacetylfentanyl), carried out by the extended Scientific Committee of the EMCDDA on 21 March 2018. O[...]Document multimédia
This miniguide is one of a larger set, which together comprise Health and social responses to drug problems: a European guide. It provides an overview of the most important aspects to consider when planning or delivering health and social respon[...]Rapport
A better understanding of the complex science of 'addiction' can improve responses to drug problems. This report contains a critical review of existing addiction theories and explores how these can be organised into an overarching structure to i[...]Rapport
This report provides an overview of the changes in cannabis policies in the Americas and the evidence emerging from evaluations of their impact. Highlighting the challenges in monitoring and evaluating regulatory changes in the drugs field, it w[...]Rapport
FRANÇAIS : Ce rapport explore la manière dont, à travers des enquêtes sur des populations ciblées, sont recueillies des données sur l'usage de drogues dans l'espace récréatif public (pubs, bars, clubs, scènes musicales) et privé en Europe. Il r[...]Rapport
This technical report focuses on an elimination barometer for viral hepatitis to help countries assess progress towards eliminating hepatitis C and B among people who inject drugs (PWID). The barometer is being developed by the EMCDDA together w[...]Rapport
Drug-related mortality is a complex phenomenon, which accounts for a considerable percentage of deaths among young people in many European countries. The EMCDDA, in collaboration with national experts, has defined an epidemiological indicator wi[...]Rapport
OEDT = EMCDDA ; I. GIRAUDON ; M. BUSTER ; A. ESPELT ; J. MATIAS ; J. VICENTE | Lisbon : OEDT / EMCDDA | EMCDDA Papers, ISSN 2315-1463 | 2015This paper examines the overall number of lives lost due to drug use. All-cause mortality among problem drug users is investigated by means of cohort studies, which link data from death registries to drug treatment records. Building on earlier w[...]Rapport
This Selected issue focuses on mortality among drug users due to all causes, of which drug-induced deaths (overdoses) is only a component, albeit the one most well-documented. The publication begins with an introduction to mortality cohort studi[...]Rapport
This publication presents the data and findings of the risk assessment on MT-45 (1-cyclohexyl-4-(1, 2-diphenylethyl)piperazine), carried out by the extended Scientific Committee of the EMCDDA on 16 September 2014. The main part of the publicatio[...]Rapport
OEDT = EMCDDA ; F. FAGGIANO ; R. MOLINAR | Lisbon : OEDT / EMCDDA | EMCDDA Papers, ISSN 2315-1463 | 2014During adolescence, some young people may experiment with both licit and illicit substances (alcohol, tobacco, cannabis and other drugs). This can have an impact on their behaviour, their relationships with others and how they function in societ[...]Rapport
FRANÇAIS : Cette « Question particulière » de l'OEDT concernant la recherche nationale en matière de drogue en Europe décrit brièvement le cadre dans lequel la recherche en matière de drogue est menée dans les pays européens. Elle examine plus[...]Rapport
This workbook is part of a series intended to educate programme planners, managers, staff and other decision-makers about the evaluation of services and systems for the treatment of psychoactive substance use disorders. This workbook describes s[...]Rapport
OEDT = EMCDDA ; V. AUWÄRTER ; J. DE MORAIS ; A. GALLEGOS ; M. EVANS-BROWN ; R. CHRISTIE ; R. JORGE ; R. SEDEFOV | Lisbon : OEDT / EMCDDA | Rapid communication | 2021This report provides a technical review of the current body of knowledge regarding new benzodiazepines that are monitored by the EU Early Warning System. The aims of this report are to strengthen situational awareness of new benzodiazepines in E[...]Rapport
This paper gives an overview of some recent developments in the tools most commonly used to manage national drug policies: strategies, coordination mechanisms and evaluations. It is based on an analysis of reports on national drug policies compi[...]Rapport
This update from the EU Early Warning System overviews the NPS situation in Europe in 2020-2021 and highlights emerging threats to support early warning, preparedness planning and response measures. In addition, it reflects on the changes and th[...]Rapport
OEDT = EMCDDA ; M. EVANS-BROWN ; A. GALLEGOS ; R. CHRISTIE ; R. JORGE ; J. DE MORAIS ; A. ALMEIDA ; R. SEDEFOV | Lisbon : OEDT / EMCDDA | Rapid communication | 2020In this update from the the EU Early Warning System aims to provide insights into what is happening with new psychoactive substances in Europe, based on data from the agency's early warning and risk-assessment activities. The report covers the p[...]Rapport
OEDT = EMCDDA ; M. EVANS-BROWN ; A. GALLEGOS ; W. FRANCIS ; R. CHRISTIE ; A. CUNNINGHAM ; J. SEKULA ; A. ALMEIDA ; R. SEDEFOV | Lisbon : OEDT / EMCDDA | Rapid communication | 2015FRANÇAIS : De nouvelles substances psychoactives (NSP ou «nouvelles drogues») ont été détectées dans l'Union européenne l'année dernière au rythme de deux par semaine environ. Au total, 101 nouvelles substances ont été signalées au système d'al[...]Rapport
This short report provides an overview of how European countries are developing innovative legal responses to the challenges presented to public health and drug policy by the rapidly evolving market for new psychoactive substances.Rapport
The European new psychoactive substances (NPS) market has increased at a speed that established drug control laws struggle to match. Various countries have therefore introduced new legal responses to this phenomenon, based either on existing law[...]Rapport
OEDT = EMCDDA ; L. VANDAM ; P. BORLE ; L. MONTANARI ; T. SURMONT ; A. PIRONA ; D. HEDRICH ; A. GALLEGOS ; N. SINGLETON ; J. MOUNTENEY ; P. GRIFFITHS | Lisbon : OEDT / EMCDDA | Rapid communication | 2018This report looks at the use of new psychoactive substances (NPS) in prison settings. This is a rapidly developing phenomenon, but empirical data are currently scarce and patchy. There is growing evidence that NPS are responsible for a large sha[...]Chapitre
OEDT = EMCDDA | 2012FRANÇAIS : En Europe et dans le monde, les nouvelles drogues et les nouveaux modes de consommation attirent de plus en plus l'attention du monde politique, des médias et du public. Cette situation s'explique, en partie, par les évolutions des t[...]Document multimédia
FRANÇAIS : Ce mini-guide s'inscrit dans le cadre plus vaste du document intitulé "Réponses sanitaires et sociales apportées aux problèmes de drogue : un guide européen". Il fournit une vue d'ensemble des aspects les plus importants à prendre en[...]Rapport
FRANÇAIS : Ce court rapport (« snapshot ») porte sur la vente en ligne de nouvelles substances psychoactives. Alors que 170 magasins en ligne vendant de nouvelles substances psychoactives (« legal high ») et livrant à au moins un pays membre de[...]Document multimédia
This miniguide is one of a larger set, which together comprise Health and social responses to drug problems: a European guide. It provides an overview of the most important aspects to consider when planning or delivering health and social respon[...]Rapport
This report presents an analysis of the drug markets in the European Neighbourhood Policy-East region covering Armenia, Azerbaijan, Belarus, Georgia, Moldova and Ukraine. Focused on providing insights into drug production, trafficking, sale, use[...]Rapport
This report presents an analysis of the drug markets in the European Neighbourhood Policy-South region covering Algeria, Egypt, Israel, Jordan, Lebanon, Libya, Morocco, Palestine, Syria and Tunisia. Focused on providing insights into drug produc[...]Document multimédia
The use of mass media campaigns as a drug prevention intervention is relatively common, but it is not without controversy. Both policymakers and practitioners have debated the effectiveness of such campaigns in reducing drug use among young peop[...]Document multimédia
The European market for hashish is currently one of the world's largest and most profitable. About 647 tons of cannabis herb and 641 tons of hashish were consumed in the European Union in 2013 and the retail market has an overall value estimated[...]Document multimédia
Cannabis is Europe's most commonly used illicit drug, with approximately 20 million adults, or around 6% of the population aged 15-64 years, having used the drug in the last year. An indication of the public health impact of the drug can be seen[...]